Journey Medical Corporation
NASDAQ:DERMDrug Manufacturers - Specialty & Generic
+$0.06 today
- Market cap
- $104.15M
- Beta
- 1.10
- P/E (TTM)
- -17.0
- EPS (TTM)
- -$0.35
Volume 0.25M
Average 0.28M
DERM Weighted Avg Shares
Average number of basic shares outstanding during the period, used to calculate basic EPS.
Journey Medical CorporationNASDAQ: DERM
Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026
Weighted avg shares growth accelerates
Q1 FY2026 weighted avg shares of 27.31M shares rose 20.8% year over year, ahead of the +17.3% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 11.5% from the prior quarter. Over 3 fiscal years it compounded at +11.8% a year.
Context
- Weighted avg shares increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +20.8% holds above the trailing-twelve-month pace of +17.3%.
Sources:Income StatementText generated from reported figures; not investment advice.
Weighted Avg Shares history
Shares · from the income statement
- Latest · FY2025
- 24.5M USD
- Year-over-year change
- +19.9%
- 4-year CAGR
- +9.1%
| Period | Period end | Weighted Avg Shares | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 24.5M | +19.9% |
| FY2024 | 2024-12-31 | 20.43M | +12.1% |
| FY2023 | 2023-12-31 | 18.23M | +4.0% |
| FY2022 | 2022-12-31 | 17.53M | +1.2% |
| FY2021 | 2021-12-31 | 17.32M | — |
Weighted Avg Shares vs competitors
How DERM compares with its peers on the latest reported figures
- DERM's LTM Mar 2026 weighted avg shares of 25.01M shares is the 9th highest of the 10 companies compared; the peer median is 38.39M shares.
- Its year-over-year change of +17.3% is the 4th highest of 10, against a peer median of +16.1%.
- Over three fiscal years its annual growth of +11.8% compares with a peer median of +23.1%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| FY2025 | 186.8M | +259.4% | +65.2% | |
| LTM Mar 2026 | 133.64M | +18.7% | — | |
| LTM Mar 2026 | 72.2M | -3.1% | +0.4% | |
| LTM Mar 2026 | 39.55M | +13.3% | +13.9% | |
| LTM Mar 2026 | 38.39M | +2.6% | +14.7% | |
| LTM Mar 2026 | 30.27M | +10.4% | +2.8% | |
| LTM Mar 2026 | 26.2M | +16.5% | +86.2% | |
| LTM Mar 2026 | 25.93M | +788.1% | +244.4% | |
| LTM Mar 2026 | 25.01M | +17.3% | +11.8% | |
| LTM Mar 2026 | 11.89M | +16.1% | +31.6% | |
| Peer median (excluding DERM) | 38.39M | +16.1% | +23.1% | |
Competitors are the stored peer set for DERM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 63.13M | 73.67M | 79.18M | 56.13M | 61.86M |
| Cost of Revenue | 32.08M | 30.78M | 26.66M | 20.88M | 25.18M |
| Gross Profit | 31.05M | 42.89M | 52.52M | 35.26M | 36.68M |
| Gross Margin | 49.2% | 58.2% | 66.3% | 62.8% | 59.3% |
| Research & Development | 16.56M | 10.94M | 7.54M | 9.86M | 480K |
| Selling, General & Admin | 39.83M | 59.47M | 43.91M | 40.2M | 44.37M |
| Operating Expenses | 65.93M | 70.41M | 54.59M | 48.93M | 44.85M |
| Depreciation & Amortization | 2.56M | 4.37M | 3.86M | 3.52M | 4.35M |
| EBITDA | (32.77M) | (23.18M) | 1.92M | (8.4M) | (3.33M) |
| EBITDA Margin | -51.9% | -31.5% | 2.4% | -15.0% | -5.4% |
| Operating Income | (34.88M) | (27.52M) | (2.07M) | (13.68M) | (8.17M) |
| Operating Margin | -55.2% | -37.4% | -2.6% | -24.4% | -13.2% |
| Interest Income | 2K | 60K | 322K | 757K | 589K |
| Interest Expense | 7.03M | 2.02M | 1.7M | 2.7M | 3.7M |
| Other Income / Expenses | (7.48M) | (2.05M) | (1.56M) | (934K) | (3.2M) |
| Income Before Tax | (42.36M) | (29.57M) | (3.63M) | (14.61M) | (11.37M) |
| Pre-Tax Margin | -67.1% | -40.1% | -4.6% | -26.0% | -18.4% |
| Income Tax Expense | 1.63M | 63K | 221K | 61K | 60K |
| Net Income | (43.99M) | (29.63M) | (3.85M) | (14.67M) | (11.43M) |
| Net Margin | -69.7% | -40.2% | -4.9% | -26.1% | -18.5% |
| EPS (Basic) | (2.54) | (1.69) | (0.21) | (0.72) | (0.47) |
| EPS (Diluted) | (2.54) | (1.69) | (0.21) | (0.72) | (0.47) |
| Weighted Avg Shares | 17.32M | 17.53M | 18.23M | 20.43M | 24.5M |
| Weighted Avg Shares (Diluted) | 17.32M | 17.53M | 18.23M | 20.43M | 24.5M |
Journey Medical Corporation
NASDAQ:DERM
Intrinsic Alpha fair value
Locked
Current Price
$3.69
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.